Bolt Biotherapeutics, Inc. — Director's Dealing 2023

Feb 7, 2023

SEC Form 5 — Annual Statement of Changes in Beneficial Ownership

Issuer: Bolt Biotherapeutics, Inc. (BOLT)
CIK: 0001641281
Period of Report: 2022-12-31

Reporting Person: Quinn William P. (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-06-06	Common Stock	P	2500	$1.6405	Acquired	22654	Direct
2022-12-06	Common Stock	P	1789	$1.1815	Acquired	24443	Direct

Footnotes

F1: Shares acquired under the issuer's Employee Stock Purchase Plan.